ECE2024 Rapid Communications Rapid Communications 5: Pituitary and Neuroendocrinology | Part I (8 abstracts)
Clinical use of 18F-fluoro-ethyl-tyrosine PET co-registered with MRI for diagnostic dilemmas in prolactinoma
Victoria van Trigt 1 , Leontine Bakker 1 , Ling Lu 2 , Iris Pelsma 1 , Marco Verstegen 3 , Wouter van Furth 3 , Lenka Pereira Arias-Bouda 2 & Nienke Biermasz 1
1Leiden University Medical Center, Department of Medicine, Division of Endocrinology, Leiden, Netherlands; 2Leiden University Medical Center, Department of Radiology, Section of Nuclear Medicine, Leiden, Netherlands; 3Leiden University Medical Center, Department of Neurosurgery, Leiden, Netherlands
Purpose : To assess the utility of (18F)fluoroethyl-L-tyrosine PET co-registered with magnetic resonance imaging (FET-PET/MRICR) in patients with difficult-to-localize prolactinoma to inform clinical decision making and treatment planning.
Methods: Retrospective cohort study of 17 consecutive patients with difficult-to-localize prolactinoma undergoing FET-PET/MRICR between October 2020 and Amgust 2022 for either (1) additional information in case of difficult remnants after transsphenoidal surgery (TSS) or pharmacological treatment, or (2) diagnosis in absence of a (clear) adenoma on conventional MRI at diagnosis or after treatment.
Results: FET-PET/MRICR identified a lesion in 14/17 patients, yet failed to identify active lesions in 2 patients with negative conventional MRI but prolactin >7.5 times upper limit of normal. FET-PET/MRICR results were inconclusive in 1 patient due to diffuse tracer uptake 10 weeks post-surgery. Foci on FET-PET/MRICR corresponded completely with the lesion on conventional MRI in 10 patients, partially in 3 patients, and new foci were identified in 4 patients. Functional imaging influenced clinical decision making in 15/17 patients: 7 patients underwent TSS after functional imaging, and 8 patients did not. One patient underwent surgery despite negative FET-PET/MRICR due to a high need for alternative treatment, and 1 patient underwent additional diagnostics due to inconclusive FET-PET/MRICR results. FET-PET/MRICR results were confirmed in all patients undergoing surgery: intraoperatively by identification of adenoma tissue in 5/8 patients, by positive histopathology in 6/8 patients, and by significant decrease in prolactin postoperatively in 7/8 patients. The surgical goal was achieved in 7/8 patients.
Conclusion: FET-PET/MRICR can be of added value in the preoperative decision-making process for selected patients with difficult to localize prolactinoma (remnants), or patients lacking a substrate on conventional MRI.
Volume 99
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more